INDEX
ABOUT JUNSHI
THERAPEUTIC AREAS
PRESS RELEASES
CAREERS
INVESTORS
CONTACT
Entrance
中文简体
中文繁体
EN
Menu
INDEX
ABOUT JUNSHI
THERAPEUTIC AREAS
PRESS RELEASES
CAREERS
INVESTORS
CONTACT
中文简体
中文繁体
EN
PRESS RELEASES
FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
07-06
2022
Junshi Biosciences Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022
06-07
2022
Toripalimab in Combination with TP Chemotherapy as 1st-Line Treatment of ESCC Approved in China
05-16
2022
Junshi Biosciences and Coherus Announce Toripalimab Granted ODD for SCLC in the US
04-13
2022
More
Back
List
//
